摘要
目的分析阿扎胞苷联合Bcl-2抑制剂维奈克拉治疗老年急性髓系白血病的效果。方法抽取南阳市中心医院2018年12月至2022年12月收治的74例老年急性髓系白血病患者,依据掷硬币法分为研究组和对照组,各37例。对照组采用DA方案治疗,研究组在对照组的基础上加用阿扎胞苷、Bcl-2抑制剂维奈克拉。对比两组临床效果、血液指标(骨髓细胞原始比例、血小板计数、血红蛋白)、免疫功能(T淋巴细胞亚群CD3^(+)、CD4^(+))、干扰素-γ(IFN-γ)、肿瘤坏死因子-α(TNF-α)、不良反应情况、生活质量(QOL)评分。结果研究组疾病缓解率较对照组高(P<0.05)。治疗后,研究组骨髓细胞原始比例较对照组少,血小板计数、血红蛋白较对照组高,CD3^(+)、CD4^(+)、IFN-γ、QOL评分较对照组高,TNF-α水平较对照组低(P<0.05)。两组不良反应发生率差异无统计学意义(P>0.05)。结论阿扎胞苷联合Bcl-2抑制剂维奈克拉治疗老年急性髓系白血病,能调节免疫功能和炎症反应,可改善血液指标,提高疾病缓解率,能改善生活质量,且具有安全性。
Objective To analyse the effect of azacitidine combined with Bcl-2 inhibitor venetoclax in the treatment of senile acute myeloid leukemia.Methods A total of 74 elderly patients with acute myeloid leukemia treated in Nanyang Central Hospital from December 2018 to December 2022 were extracted,and divided into study group and control group based on a coin toss,with 37 cases in each group.The control group was treated with DA regimen,and the study group was additionally treated with azacytoside and Bcl-2 inhibitor Vinecra.Compared two groups of clinical effect and blood index(original proportion of bone marrow cells,platelet count,hemoglobin),immune function(T lymphocyte subsets CD3^(+),CD4^(+)),interferonγ(IFN-γ),tumor necrosis factor alpha(TNF-α),adverse reactions and quality of life(QOL)score.Results The remission rate in the study group was higher than that in the control group(P<0.05).After treatment,the original proportion of bone marrow cells in the study group was lower than that in the control group,while platelet count and hemoglobin were higher.CD3^(+),CD4^(+),IFN-γ,and QOL scores were higher than those in the control group,and TNF-αlevel was lower than that in the control group(P<0.05).There was no statistically difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Azacitidine combined with Bcl-2 inhibitor venetoclax in the treatment of elderly patients with acute myeloid leukemia can regulate immune function and inflammatory response,improve blood indexes,improve the remission rate of disease,and improve the quality of life,with high safety.
作者
尚淼
段丽娟
贺莹
SHANG Miao;DUAN Lijuan;HE Ying(Department of Hematology,Nanyang Central Hospital,Nanyang 473001,China)
出处
《河南医学研究》
CAS
2024年第18期3422-3425,共4页
Henan Medical Research
关键词
老年急性髓系白血病
阿扎胞苷
维奈克拉
疗效
elderly patients with acute myeloid leukemia
azacitidine
venetoclax
curative effect
